Диссертация (1141189), страница 23
Текст из файла (страница 23)
ten Berg, R. Marcucci et al. // Journal of the American College ofCardiology. – 2011. – Vol. 58, № 19. – P. 1945 -1954.61.!Price, M.J. Standard- vs high-dose clopidogrel based on platelet functiontesting after percutaneous coronary intervention: the GRAVITAS randomized trial /M.J. Price, P.B. Berger, P.S. Teirstein et al. // JAMA. – 2011. – Vol.
305, № 11. – P.1097 –1105.62.!Price, M.J. Platelet reactivity and cardiovascular outcomes after percutaneouscoronary intervention: a time-dependent analysis of the Gauging Responsiveness with148!a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial /M.J. Price, D.J. Angiolillo, P.S. Teirstein et al. // Circulation. – 2011.
– Vol. 124, №10. - P. 1132 - 1137.63.!Stone, G.W. Platelet reactivity and clinical outcomes after coronary arteryimplantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registrystudy / G.W Stone, B. Witzenbichler, G. Weisz et al. // Lancet. – 2013. – Vol. 382, №9892. – P. 614 - 623.64.!Kirtane, A.J. Impact of point-of-care platelet function testing among patienswith and without acute coronary syndromes undergoing PCI with drug-eluting stent: anADAPT-DES substudy / A.J. Kirtane, M. Rinaldi, H. Parise et al. // Journal of theAmerican College of Cardiology.– 2012. – Vol.
59, № 13. - P. E291.65.!Collet, J.P. Bedside monitoring to adjust antiplatelet therapy for coronarystenting / J.P. Collet, T. Cuisset, G. Rangé, et al. // New England Journal of Medicine.– 2012. – Vol. 367, №22. – P. 2100 – 2109.66.!Patti, G. Usefulness of Platelet Response to Clopidogrel by Point-of-CareTesting to Predict Bleeding Outcomes in Patients Undergoing Percutaneous CoronaryIntervention (from the Antiplatelet Therapy for Reduction of Myocardial DamageDuring Angioplasty-Bleeding Study / G.
Patti, M. Demail, V. Pasceri et al. // Journalof the American College of Cardiology. – 2011. – Vol. 107, № 7. – P. 995 – 1000.67.!Morange, P.E. Haemostatic factors and the risk of cardiovascular death inpatients with coronary artery disease: the AtheroGene study / P.E. Morange, C. Bickel,V. Nicaud et al. // Arteriosclerosis, Thrombosis, and Vascular Biology.
– 2006. – Vol.26, № 12. – P. 2793 - 2799.68.!Комаров, А.Л. Д-димер и функция тромбоцитов как предикторытромботических осложнений у больных с атеросклеротическим поражениемартерий нижних конечностей (результаты 5-летнего наблюдения) / А.Л. Комаров// Кардиология. – 2000. – № 9.
– C. 16 - 22.69.!Meade, T.W. Haemostatic function and cardiovascular death: early results of aprospective study / T.W. Meade, W.R. North, R. Chakrabarti et al. // Lancet. – 1980. –Vol. 1, № 8177. – P. 1050 - 1054.149!70.!Thompson, S.G. Hemostatic factors and the risk of myocardial infarction orsudden death in patients with angina pectoris. European Concerted Action onThrombosis and Disabilities Angina Pectoris Study Group / S.G.
Thompson, J.Kienast, S.D. Pyke et al. // New England Journal of Medicine. – 1995. – Vol. 332, №10. – P. 635 - 641.71.!Kaptoge, S. The Emerging Risk Factors Collaboration. C-Reactive Protein,Fibrinogen, and Cardiovascular Disease Prediction / S. Kaptoge, E. Di Angelantonio,L. Pennells // New England Journal of Medicine. – 2012. – Vol. 4, № 367. – P.
1310 –1320.72.!Баркаган, З.С. Диагностика и контролируемая терапия нарушенийгемостаза / З.С. Баркаган, А.П. Момот. – М.: Ньюдиамед, 2001. – 286 с.73.!Cate-Hoek, A.J. Management studies using a combination of D- dimer testresult and clinical probability to rule out venous thromboembolism: a systematicreview / A.J. Cate-Hoek, M.H. Prins // Journal of Thrombosis and Haemostasis. –2005. – Vol. 3, № 11. – P.
2465 - 2470.74.!Lip, G.Y. D-dimer: a useful clinical marker of thrombogenesis? / G.Y. Lip,G.D. Lowe // Fibrin Clin Sci (Lond). – 1995. – Vol. 89, № 3. – P. 205 - 214.75.!Charoensri, N. D-dimer plasma levels in NSTE-ACS patient / N. Charoensri, S.Pornratanarangsi // Journal of the Medical Association of Thailand – 2011. – Vol. 94(Suppl 1.). – S 39 - 45.76.!Volschan, A. D-dimer for myocardial infarction diagnosis in patients withacute coronary syndrome admitted to a chest pain unit / A.
Volschan, E.T. Mesquita,M. Silva et al. // Critical Care. – 2005. Vol. 9 (Suppl 2). – P. 15.77.!Komarov,A.D-dimer,plasmin-antiplasmincomplexandmatrixmetalloproteinase 2 as markers of cardiovascular events in patients with stablecoronary disease / A. Komarov, T. Ilyushchenko, A. Dobrovolsky et al.// Abstract ofthe ESC Congress 2012. European Heart Journal. – 2012.
– Vol. 33 (AbstractSupplement). - P. 305.78.!Гуськова, Е.В. Показатели гемостаза и прогноз тромботических игеморрагических осложнений у больных ИБС после плановых чрескожных150!коронарных вмешательств / Е.В. Гуськова, Е.П. Панченко, А.Л. Комаров и соавт.// Кардиологический вестник. – 2015. – №3. – C. 54 – 63.79.!Morange, P.E. Haemostatic factors and the risk of cardiovascular death inpatients with coronary artery disease: the AtheroGene study / P.E. Morange, C.
Bickel,V. Nicaud et al. // Arteriosclerosis, Thrombosis, and Vascular Biology. – 2006. – Vol.26, № 12. – P. 2793 - 2799.80.!Папаян, Л.П. Д-димер в клинической практике / Л.П. Папаян, Е.С:Князева – Пособие для врачей. - М.: ООО "Инсайтполиграфик", 2002. - 20 с.81.!Gorog, D.A. Prognostic value of plasma fibrinolysis activation markers incardiovascular disease / D.A.
Gorog // Journal of the American College of Cardiology.– 2010. – Vol. 55, № 24. – P. 2701 – 2709.82.!Scott, S.A. Clinical pharmacogenetics implementation consortium guidelinesforCYP2C19 genotype and clopidogrel therapy: 2013 update / S.A. Scott, K. Sangkuhl,C.M. Stein et al. // Clinical Pharmacology and Therapeutics. – 2013.
– Vol. 94, № 3. –P. 317 – 323.83.!Панченко, Е. П. Фармакогенетика клопидогрела и ее клиническоезначение / Е.П. Панченко, А.Л. Комаров // Кардиология. – 2012. – № 52, № 9. – C.44 - 52.84.!Harmsze, A.M. CYP2C19*2 and CYP2C9*3 alleles are associated with stentthrombosis: a case-control study / A.M. Harmsze, J.W. van Werkum, J.M. Ten Berg etal. // European Heart Journal. – 2010. – Vol. 31, №24.
– P. 3046 - 3053.85.!Harmsze, A.M. The influence of CYP2C19*2 and *17 on on-treatment plateletreactivity and bleeding events in patients undergoing elective coronary stenting / A.M.Harmsze, J.W. van Werkum, C.M. Hackeng et al. // Pharmacogenetics and Genomics.– 2012. - Vol.
22, № 3. – P. 169 - 175.86.!Sibbing, D. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleedingevents, and stent thrombosis in clopidogrel-treated patients with coronary stentplacement / D. Sibbing, W. Koch, D. Gebhard et al. // Circulation. – 2010. – Vol. 121,№ 4. - P. 512 - 518.151!87.!Zabalza, M. Meta-analyses of the association between cytochrome CYP2C19loss- and gain-of-function polymorphisms and cardiovascular outcomes in patientswith coronary artery disease treated with clopidogrel / M. Zabalza, I Subirana, J.
Salaet al. // Heart. – 2012. – Vol. 98, №2. – P. 100 - 108.88.!Li, Y. The gain-of-function variant allele CYP2C19*17: a double-edged swordbetween thrombosis and bleeding in clopidogrel-treated patients / Y. Li, H.L. Tang,Y.F. Hu, H.G. Xie // Journal of Thrombosis and Haemostasis. – 2012 – Vol. 10, № 2. –P. 199 - 206.89.!Holmes, M.V. CYP2C19 genotype, clopidogrel metabolism, platelet function,and cardiovascular events: a systematic review and meta-analysis / M.V. Holmes, P.Perel, T. Shah et al.
// JAMA. – 2011. – Vol. 306, №24. – P. 2704 - 2714.90.!Bauer, T. Impact of CYP2C19 variant genotypeson clinical efficacy ofantiplatelet treatment with clopidogrel: systematic review and meta-analysis / T. Bauer,H.J. Bouman, J.W. van Werkum et al. // British Medical Journal. – 2011. – Vol. 343. –P. 1 - 18.91.!Wallentin, L. Ticagrelor versus clopidogrel in patients with acute coronarysyndromes / L. Wallentin, R.C. Becker, A.
Budaj et al. the PLATO Investigators //New England Journal of Medicine. – 2009. – Vol. 361, №11. – P. 1045 – 1057.92.!Urban, P. Stent thrombosis and bleeding complications after implantation ofsirolimus-eluting coronary stents in anunselected worldwide population: a report fromthe e-SELECT (Multi-Center Post-Market Surveillance) registry / P. Urban, A.Abizaid, A. Banning et al. // Journal of the American College of Cardiology. – 2011. –Vol. 57, № 13.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
